Please assess the completion status of the following clinical trial:

Trial Title: Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Male or female, aged ≥18 years age~* Type 2 DM (diet-controlled or on stable treatment) or prediabetes~  * Stable treatment defined as no change in oral therapy agents or doses for diabetes mellitus and (where applicable) \<10% change in average total daily insulin dose over last 6 weeks~ * HbA1c ≤97 mmol/mol (11%) (routine available data from medical records, recorded in the last year)~ * Prediabetes defined as HbA1c 39-47 mmol/mol (5.7-6.4%) at the time of screening (specifically for the prediabetes group, HbA1c will be repeated at the time of screening if there are no recent results within the last 3 months, in order to confirm the diagnosis of prediabetes)~* Heart failure (as defined by the presence of typical signs and symptoms of heart failure with documented reduced ejection fraction (ref SIGN and ESC guidelines))~  * NYHA class II-IV~ * LVEF ≤40%~ * On stable doses of ACEI, ARB or ARNI for 4 weeks prior to randomisation unless contraindicated or not tolerated. They should also be taking a beta-blocker at a stable dose for 4 weeks unless contraindicated or not tolerated~* Women of childbearing potential (WOCBP) must be currently adhering to, or be willing to use, highly effective birth control methods for study treatment duration including:~  * Combined hormonal contraception (oestrogen and progestogen containing medication) either orally, intravaginally, or transdermally~ * Progesterone only hormonal contraception either orally, injected, or implanted~ * Intrauterine device (IUD)~ * Intrauterine hormone release system (IUS)~ * Bilateral fallopian tube occlusion~ * Vasectomised partner~ * Complete sexual abstinence where this is their preferred and usual lifestyle~WOCBP comprises women who have experienced menarche and who have not undergone successful surgical sterilisation (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who are not post-menopausal. Post-menopausal is defined as:~o Women who have had amenorrhea for ≥12 consecutive months (without another medical cause)~Exclusion Criteria:~* Type 1 DM~* History of hospital admission with a diagnosis of diabetic ketoacidosis (DKA)~* Insulin use within 1 year of diagnosis of diabetes~* History of acute or chronic pancreatitis~* eGFR \<30 ml/min/1.73m2 (derived using CKD EPI)~* Persistent/permanent atrial fibrillation/flutter (conditions which significantly impede MRI image interpretability)~* Acute coronary syndrome, stroke or surgery within 1 month (small type 2 MI in the context of acute HF does not apply)~* BMI \>52 kg/m2~* Liver disease, defined by serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal (ULN) during screening~* Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption~* Any condition outside the cardiovascular and renal disease area, such as but not limited to malignancy, with a life expectancy of less than 2 years based on investigator's clinical judgement~* Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma, adjuvant hormonal therapy for breast cancer and hormone therapy for prostate cancer)~* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g. malaria, babesiosis, haemolytic anaemia)~* Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent~* Any uncontrolled endocrine disorder except Type 2 DM~* Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake~* Known hypersensitivity to the empagliflozin or excipients~* Known hypersensitivity to gadolinium~* Inability to give informed consent~* SGLT2 inhibitor use (current or previous)~* Devices or any other contraindication to MRI scans~* Currently pregnant, planning pregnancy, or currently breastfeeding~* History of previous lower limb amputation~* Current participation in another interventional medical study or within the last 90 days~* Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Empagliflozin 10mg tablets for oral self-administration once daily
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): placebo tablets for oral self-administration once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).